A pilot study found that oral administration of GSH (300 mg/day) for 4 months can decrease ALT levels and hepatic steatosis in Japanese NAFLD patients, in those without severe fibrosis or uncontrolled diabetes. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.